Press releases & announcements
10 January, 2018
RhoVac AB (“RhoVac”) has hired Alexandra Ellervik to the Communication and Project Manager position. The recruitment means strengthening the organization, enabling the company to ensure continuation of high rate development... [Read more]
13 December, 2017
RhoVac AB (“RhoVac”) announced today, 13 December 2017 that the company has obtained positive INFγ ELIspot results showing that seven out of eight patients tested, respond to the RV001 vaccine... [Read more]
5 December, 2017
RhoVac AB is expanding its international presence by attending conferences and by increasing activity on digital media
In alignment with company’s strategy to license or sell, whole or part of operations, following completion of the ongoing phase I/II clinical trial, RhoVac AB (“RhoVac”) is attending business meetings... [Read more]
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.